Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Gan

Showing results (291-300 of 326) with videos related to

Pageof 33
Sort By:
Nature Communications|July 21, 2020
The emergence of magnetic ordering at complex oxide interfaces tuned by defectsD-S Park, A D Rata, I V Maznichenko, et al.
Journal of Medicinal Chemistry|August 28, 1998
New cyclooxygenase-2/5-lipoxygenase inhibitors. 3. 7-tert-butyl-2, 3-dihydro-3,3-dimethylbenzofuran derivatives as gastrointestinal safe antiinflammatory and analgesic agents: variations at the 5 positionJ M Janusz, P A Young, J M Ridgeway, et al.
European Journal of Cancer (Oxford, England : 1990)|May 11, 2021
Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trialsChun L Gan, Igor Stukalin, Daniel E Meyers, et al.
European Journal of Cancer (Oxford, England : 1990)|June 19, 2022
Outcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapyJeffrey Graham, John Connor Wells, Shaan Dudani, et al.
Brain Stimulation|April 15, 2020
Safety and tolerability of transcranial magnetic and direct current stimulation in children: Prospective single center evidence from 3.5 million stimulationsE Zewdie, P Ciechanski, H C Kuo, et al.
Journal of Geriatric Oncology|March 6, 2021
Efficacy of immune-checkpoint inhibitors (ICI) in the treatment of older adults with metastatic renal cell carcinoma (mRCC) - an International mRCC Database Consortium (IMDC) analysisDaniel V Araujo, J Connor Wells, Aaron R Hansen, et al.
Journal of Medicinal Chemistry|April 17, 1998
New cyclooxygenase-2/5-lipoxygenase inhibitors. 2. 7-tert-butyl-2,3-dihydro-3,3-dimethylbenzofuran derivatives as gastrointestinal safe antiinflammatory and analgesic agents: variations of the dihydrobenzofuran ringJ M Janusz, P A Young, M W Scherz, et al.
Journal of Medicinal Chemistry|April 17, 1998
New cyclooxygenase-2/5-lipoxygenase inhibitors. 1. 7-tert-buty1-2,3-dihydro-3,3-dimethylbenzofuran derivatives as gastrointestinal safe antiinflammatory and analgesic agents: discovery and variation of the 5-keto substituentJ M Janusz, P A Young, J M Ridgeway, et al.
JAMA Ophthalmology|June 24, 2021
Development and Validation of a Preference-Based Glaucoma Utility Instrument Using Discrete Choice ExperimentEva K Fenwick, Semra Ozdemir, Ryan E K Man, et al.
The Journal of Animal Ecology|April 4, 2025
Understanding and predicting animal movements and distributions in the AnthropoceneSara Gomez, Holly M English, Vanesa Bejarano Alegre, et al.
Pageof 33

Showing results (291-300 of 326) with videos related to

Sort By:
Pageof 33
Nature Communications|July 21, 2020
The emergence of magnetic ordering at complex oxide interfaces tuned by defectsD-S Park, A D Rata, I V Maznichenko, et al.
Journal of Medicinal Chemistry|August 28, 1998
New cyclooxygenase-2/5-lipoxygenase inhibitors. 3. 7-tert-butyl-2, 3-dihydro-3,3-dimethylbenzofuran derivatives as gastrointestinal safe antiinflammatory and analgesic agents: variations at the 5 positionJ M Janusz, P A Young, J M Ridgeway, et al.
European Journal of Cancer (Oxford, England : 1990)|May 11, 2021
Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trialsChun L Gan, Igor Stukalin, Daniel E Meyers, et al.
European Journal of Cancer (Oxford, England : 1990)|June 19, 2022
Outcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapyJeffrey Graham, John Connor Wells, Shaan Dudani, et al.
Brain Stimulation|April 15, 2020
Safety and tolerability of transcranial magnetic and direct current stimulation in children: Prospective single center evidence from 3.5 million stimulationsE Zewdie, P Ciechanski, H C Kuo, et al.
Journal of Geriatric Oncology|March 6, 2021
Efficacy of immune-checkpoint inhibitors (ICI) in the treatment of older adults with metastatic renal cell carcinoma (mRCC) - an International mRCC Database Consortium (IMDC) analysisDaniel V Araujo, J Connor Wells, Aaron R Hansen, et al.
Journal of Medicinal Chemistry|April 17, 1998
New cyclooxygenase-2/5-lipoxygenase inhibitors. 2. 7-tert-butyl-2,3-dihydro-3,3-dimethylbenzofuran derivatives as gastrointestinal safe antiinflammatory and analgesic agents: variations of the dihydrobenzofuran ringJ M Janusz, P A Young, M W Scherz, et al.
Journal of Medicinal Chemistry|April 17, 1998
New cyclooxygenase-2/5-lipoxygenase inhibitors. 1. 7-tert-buty1-2,3-dihydro-3,3-dimethylbenzofuran derivatives as gastrointestinal safe antiinflammatory and analgesic agents: discovery and variation of the 5-keto substituentJ M Janusz, P A Young, J M Ridgeway, et al.
JAMA Ophthalmology|June 24, 2021
Development and Validation of a Preference-Based Glaucoma Utility Instrument Using Discrete Choice ExperimentEva K Fenwick, Semra Ozdemir, Ryan E K Man, et al.
The Journal of Animal Ecology|April 4, 2025
Understanding and predicting animal movements and distributions in the AnthropoceneSara Gomez, Holly M English, Vanesa Bejarano Alegre, et al.
Pageof 33